HPRT1

Hypoxanthine-guanine phosphoribosyltransferase · P00492 · HPRT1 on Sugi Atlas →

31,141 patent compounds predicted against HPRT1, 14,594 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL97316	0.75	18/20
SCHEMBL84257	0.81	17/20
SCHEMBL173060	0.81	17/20
SCHEMBL97295	0.64	17/20
Leteprinim (SCHEMBL358491)	0.50	16/20
SCHEMBL172846	0.70	15/20
Phosphoric Acid (SCHEMBL571369)	0.64	15/20
SCHEMBL64568	1.00	14/20
SCHEMBL84258	1.00	14/20
Omaciclovir (SCHEMBL571367)	0.66	14/20
Gs-438 (SCHEMBL64567)	0.71	13/20
SCHEMBL455645	0.62	13/20
SCHEMBL571368	0.61	12/20
Omaciclovir (SCHEMBL417577)	0.61	12/20
Lobucavir (SCHEMBL457255)	0.56	12/20
Lobucavir (SCHEMBL457256)	0.56	12/20
SCHEMBL147641	0.67	11/20
SCHEMBL572051	0.59	11/20
SCHEMBL172847	0.55	11/20
Valomaciclovir (SCHEMBL417653)	0.52	11/20

Clinical trials — most relevant to HPRT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy	PHASE4	COMPLETED
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia	PHASE2	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity	PHASE2	COMPLETED
Thiopurine EnhAnced Maintenance Therapy	PHASE1/PHASE2	COMPLETED
Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy	PHASE1/PHASE2	COMPLETED
Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome	PHASE2	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Purine Metabolism Enzyme SNP to Uric Acid Production	nan	COMPLETED
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan	nan	UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Correlation of Genetic Polymorphism of Azathioprine Metabolizing Enzymes and Correlation to Clinical Adverse Effects	nan	COMPLETED
Vitamin B Therapy for Hyperlactatemia	nan	COMPLETED
A RETROspective Study of Patients With TK2d	nan	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer	nan	COMPLETED
Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia	nan	COMPLETED
The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Cost-effectiveness of TPMT Pharmacogenetics	nan	COMPLETED
Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524	nan	COMPLETED
Low-Dose Weekly vs High-Dose Cisplatin	nan	RECRUITING
An EQA Scheme for TPMT Activity and Thiopurine Metabolites	nan	UNKNOWN
C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine Effectiveness in Metastatic Colon Cancer	nan	UNKNOWN
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients.	nan	COMPLETED
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HPRT1 binder may also engage these)

Protein	Name	Similarity
Q6LDD9	—	1.000	Q6LDD9 →
A5A6I1	—	1.000	A5A6I1 →
Q9W719	—	1.000	Q9W719 →
Q45FY6	—	1.000	Q45FY6 →
P47959	—	1.000	P47959 →
Q3SZ18	—	1.000	Q3SZ18 →
P27605	—	1.000	P27605 →
P00493	—	1.000	P00493 →
Q6WIT9	—	1.000	Q6WIT9 →
Q64531	—	1.000	Q64531 →
P00494	—	1.000	P00494 →
Q9NRG1	—	0.995	Q9NRG1 →
Q6DCP3	—	0.994	Q6DCP3 →
P20035	—	0.993	P20035 →
P07833	—	0.992	P07833 →
A4II60	—	0.991	A4II60 →
Q07010	—	0.987	Q07010 →
Q26997	—	0.987	Q26997 →
Q8VYB2	—	0.985	Q8VYB2 →
Q9HE15	—	0.985	Q9HE15 →
Q26998	—	0.984	Q26998 →
Q27541	—	0.983	Q27541 →
Q55EL3	—	0.983	Q55EL3 →
O65583	—	0.983	O65583 →
Q9LTY6	—	0.982	Q9LTY6 →
Q9LK34	—	0.981	Q9LK34 →
P43152	—	0.981	P43152 →
Q68EH8	—	0.981	Q68EH8 →
Q91YL3	—	0.980	Q91YL3 →
Q9FKS0	—	0.980	Q9FKS0 →